Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons

Kidney International

Volumn 78, Issue 2, 2010, Pages 152-159

  Tillou, Xavier ^a,b   Poirier, Nicolas ^a   Le Bas Bernardet, Stéphanie ^a   Hervouet, Jeremy ^a   Minault, David ^a   Renaudin, Karine ^c   Vistoli, Fabio ^a   Karam, Georges ^a   Daha, Mohamed ^d   Soulillou, Jean Paul ^a   Blancho, Gilles ^a  

^a INSERM   (France)

^b University Medical Center   (France)

^c HÔTEL DIEU   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alloantibodies; antibody mediated rejection; complement regulation; kidney allograft; nonhuman primate

Indexed keywords

COMPLEMENT INHIBITOR; HLA ANTIBODY; RECOMBINANT HUMAN COMPLEMENT C1 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; KIDNEY ALLOGRAFT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; ANTIBODIES; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT INACTIVATING AGENTS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; IMMUNIZATION; KIDNEY TRANSPLANTATION; PAPIO; RECOMBINANT PROTEINS;

EID: 77954235492     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.75     Document Type: Article

References (26)

1. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
2. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
3. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611-2618.
4. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
5. Wahrmann M, Exner M, Schillinger M et al. Pivotal role of complementfixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6: 1033-1041.
6. Gloor J, Cosio F, Lager DJ et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8: 1367-1373.
7. Becker YT, Becker BN, Pirsch JD et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
8. Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842-846.
9. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5: 2786-2790.
10. Platt JL, Saadi S. The role of complement in transplantation. Mol Immunol 1999; 36: 965-971.
11. Pruitt SK, Bollinger RR, Collins BH et al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63: 900-902.
12. Wang H, Rollins SA, Gao Z et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999; 68: 1643-1651.
13. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
14. Leventhal JR, Dalmasso AP, Cromwell JW et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-865.
15. Adams DH, Kadner A, Chen RH et al. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 2001; 8: 36-40.
16. Lin SS, Weidner BC, Byrne GW et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745-1756.
17. Kirschfink M. C1-inhibitor and transplantation. Immunobiology 2002; 205: 534-541.
18. Hecker JM, Lorenz R, Appiah R et al. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomonligus monkey kidney transplantation. Transplantation 2002; 73: 688-694.
19. Koles K, van Berkel PHC, Pieper FR et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51-64.
20. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9: 310-323.
21. Poirier N, Blancho G. Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo- and xenoantibodies. Transplant Proc 2008; 40: 581-583.
22. Poirier N, Maillet F, Barussaud M et al. Acute humoral rejection of renal transplants in alloimmunized pigs. J Surg Res 2007; 139: 261-268.
23. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
24. Davis AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol 2008; 45: 4057-4063.
25. Liu D, Lu F, Qin G et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179: 3966-3972.
26. Seelen MA, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005; 296: 187-198.